Cardiovascular Disease Risk Assessment and Management for Primary Care

Objectives

Strengthen primary prevention of cardiovascular disease (CVD) in New Zealand through population-wide health promotion and personalised five-year risk assessment, prioritising intervention according to predicted pre-treatment vascular risk and supporting informed shared decisions.[1][2]The framework uses New Zealand Primary Prevention Equations for eligible adults without prior CVD, with diabetes-specific equations for people with diabetes.[3][4]

• Promote smoking cessation, healthy eating, regular physical activity, healthy weight, lower salt and alcohol intake, and replacement of saturated fats with mono- and polyunsaturated fats.[5][6][7]
• Use five-year CVD risk to guide prevention, generally avoiding medication below 5 percent risk, individualising decisions at 5 to under 15 percent, and strongly recommending lipid-lowering and blood-pressure-lowering treatment at 15 percent or higher when relevant clinical criteria are met.[8][6]
• Prioritise treatment for people at highest predicted risk, as the absolute benefit of lipid-lowering and blood-pressure-lowering medicines is largely determined by baseline vascular risk.[1]
• Support shared, informed choices by considering estimated benefit and harm, heart age, risk trajectory, clinical circumstances, life expectancy, cost-effectiveness, and individual preferences.[9]
• Improve equity by assessing risk earlier for Māori, Pacific and South Asian peoples and recognising that standard tools may underestimate risk for people with serious mental illness, addiction, relevant psychotropic treatment, inflammatory disorders, HIV treatment, chronic kidney disease, and other specified conditions.[5][10][11]
• Optimise diabetes care through individually agreed glycaemic targets, self-management support, prevention of renal and retinal complications, and avoidance of hypoglycaemia, particularly among older, frail, or otherwise vulnerable people.[12][13]

Implementation

Deliver CVD prevention primarily through electronically supported primary care assessment, clinical judgement, risk communication, lifestyle support, targeted medicine management, and scheduled review.[3][9]The guidance was updated through a Ministry of Health-commissioned review conducted by the Heart Foundation, with University of Auckland VIEW research-group input and peer review by clinical and guideline experts.[14]

• Implement computerised decision support integrated with patient management systems, as paper charts cannot calculate risk under the new equations.[3]Enable automatic transfer of risk data to patient records, patient access to results, printable advice, and centrally updateable web-based tools.[9][8]
• Start routine assessment at age 45 for men and 55 for women, or 15 years earlier for Māori, Pacific and South Asian populations.[5]Begin assessment from age 25 for people with severe mental illness and repeat it every two years, with more frequent review at higher risk.[5]
• Calculate five-year risk for eligible men and women aged 30 to 74 years using sex-specific New Zealand equations, while using clinical judgement for people aged 75 years and over.[10][15]Do not apply primary-prevention risk tools to people with established CVD-equivalent risk, including severe renal impairment with estimated glomerular filtration rate below 30 ml/min/1.73 m², because they require aggressive or individualised management.[3][15]
• Record standardised demographic, socioeconomic, family-history, medical-history, behavioural, clinical, laboratory and medicine variables needed for risk calculation.[16][17]Communicate numerical risk alongside graphical explanations of untreated and treated risk, adverse effects, heart age and risk trajectory.[9][8]
• Incorporate CVD risk assessment into annual diabetes reviews and use diabetes-specific risk factors, including duration of diabetes, albuminuria, renal function and glycaemic control.[5][18]Screen for diabetes using glycated haemoglobin from an accredited laboratory, confirm asymptomatic results of 50 mmol/mol or higher after at least three months, and use fasting plasma glucose where glycated haemoglobin is unavailable or unreliable.[18]
• Provide tailored behavioural counselling, including self-monitoring, goal setting, barrier management, food and shopping guidance, role play, and referral or support.[7]Apply a systematic smoking-cessation process by documenting smoking status for everyone aged 15 years and older, advising people who smoke to stop, and offering support or referral to regional services.[7][19]
• Use dietary modification as the preferred initial lipid-management intervention and statins as the preferred lipid-lowering medicines.[6]Assess secondary causes of dyslipidaemia before drug treatment, use the maximum tolerated statin dose where appropriate, and manage muscle symptoms according to creatine kinase findings.[19][20]
• Measure blood pressure in the office and use validated ambulatory or home monitoring where white-coat hypertension, variable readings, resistant hypertension, or treatment-related hypotension is suspected.[6][21]Use suitable first-line medicines, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blockers and thiazide diuretics, alone or in appropriate combinations unless contraindicated.[6]
• Use shared decision-making for aspirin, statins and blood-pressure-lowering treatment where benefits and harms require individual consideration.[6][12]Avoid aspirin for primary prevention in people over 70 years and in people with five-year risk below 15 percent.[12]
• Review lipid and blood-pressure management annually once targets are achieved, and repeat CVD risk assessment after 10 years below 3 percent risk, after five years at 3 to 9 percent, after two years at 10 to 14 percent, and annually at 15 percent or higher.[5][6]Monitor physical health at least annually for people with psychosis or schizophrenia after responsibility transfers to primary care.[22]

Monitoring & Evaluation

Monitoring centres on repeated five-year cardiovascular disease risk assessment, clinical treatment targets, safety surveillance and electronic recording in primary care, while no document-wide performance-reporting or accountability framework is specified.[5][9]

• Repeat risk assessment after 10 years for five-year risk below 3 percent, after five years for risk of 3 to 9 percent, after two years for risk of 10 to 14 percent, and annually for risk of 15 percent or more.[5]
• Review people with established cardiovascular disease, people with risk above 15 percent and people with diabetes annually.[8][7]
• Record risk assessments and management advice in patient management systems, using integrated tools that automatically transfer results to the patient record and can be updated as evidence and algorithms change.[9]
• Track clinical outcomes used in the risk equations, including cardiovascular deaths and hospitalisations for ischaemic heart disease, stroke, transient ischaemic attack, heart failure and peripheral vascular disease.[3][10]
• Use PREDICT clinical assessment data linked through encrypted National Health Index numbers to national hospitalisation and mortality datasets to develop risk equations.[1]
• Monitor lipid management every 6 to 12 months until the agreed target is achieved and annually thereafter; review satisfactory lipid management annually.[20][6]
• Review blood pressure annually after the target is reached, with home monitoring and electronic communication as an option for stable people.[6][13]
• Apply treatment indicators of low-density lipoprotein cholesterol below 1.8 mmol/L for people at five-year risk of 15 percent or more, at least a 40 percent reduction when drug treatment starts at risk of 5 to 15 percent, and office blood pressure below 130/80 mmHg when treatment is commenced.[6]
• Monitor statin safety by assessing creatine kinase only for symptomatic muscle pain, tenderness or weakness; reduce or stop treatment and monitor weekly when symptomatic creatine kinase is 3 to 10 times normal, and discontinue immediately when it exceeds 10 times normal.[20]
• Monitor glycaemic control against individual targets and monitor hypoglycaemia risk from sulphonylureas, insulin and combination therapy, particularly among older or frail people.[12][13]
• Measure estimated glomerular filtration rate, albumin:creatinine ratio and serum potassium 5 to 10 days after initiating treatment for diabetic renal disease and regularly thereafter.[23]
• Confirm diabetes in asymptomatic people by repeating glycated haemoglobin testing at least three months after a result of 50 mmol/mol or higher, and repeat testing annually for people with pre-diabetes.[18]
• Maintain at least annual physical-health monitoring for people with psychosis or schizophrenia after responsibility transfers from secondary to primary care.[22]
• Recognise limitations in risk assessment, including probable underestimation for people with serious mental illness, HIV treatment, dyslipidaemia-inducing medicines or inflammatory disorders, and lack of validation of the New Zealand Primary Prevention Equations for people aged 75 to 84 years.[10][15]
• Use formal quality appraisal of international guidelines and systematic reviews, supplemented where needed by rapid systematic reviews of primary studies, to support recommendations.[14][1]

Beyond clinical review intervals, diagnostic thresholds, treatment targets, safety monitoring and electronic patient records, the material does not specify a formal indicator set, reporting schedule, implementation surveillance system, responsible accountable institution or evaluation process.[3][6][9]

Costing & Financing

Costing information is very limited: the material identifies research funders, requires consideration of cost-effectiveness in individual treatment decisions, and notes one medicine’s funding status, but specifies no programme budget, implementation allocation, quantified funding gap or economic model.[3][9][13]

• Fund research developing the risk equations jointly through the Healthier Lives National Science Challenge, the Health Research Council of New Zealand and the Heart Foundation of New Zealand.[3]
• Consider cost-effectiveness alongside expected benefits, harms, clinical circumstances, life expectancy and personal preferences when making shared decisions on cardiovascular risk management.[9]
• Recognise that pioglitazone is currently funded in New Zealand for relevant patient groups; the supplied material does not identify funding arrangements for other alternative diabetes medicines.[13]
• Note potential but unquantified cost savings from smoking cessation.[7]

No explicit budgets, expenditure amounts, service-delivery costs, financing mechanisms, resource-mobilisation plan, funding shortfall, unit cost, economic threshold, or economic assumption is specified for implementation of the cardiovascular risk assessment and management guidance.[6][14][8][20]